Impact of Early Subcutaneous Basal Insulin With Intravenous Insulin Infusion for Diabetic Ketoacidosis and Glycaemic Outcomes: A Systematic Review and Meta-Analysis.

TL;DR

Adding subcutaneous basal insulin to standard intravenous insulin therapy in diabetic ketoacidosis reduces time to metabolic recovery by approximately 4 hours and modestly decreases fluid requirements, without increasing safety risks.

What the Study Found

Diabetic ketoacidosis (DKA) is a medical emergency marked by severely elevated blood glucose, metabolic acidosis, and ketone accumulation. Standard treatment relies on continuous intravenous insulin infusion to reverse ketone production and restore normal blood chemistry. This meta-analysis examined whether adding early subcutaneous basal insulin on top of IV therapy could improve outcomes.

Researchers systematically reviewed eight randomized controlled trials involving 407 adults with DKA, comparing early basal insulin plus IV infusion against IV insulin alone. The analysis used stringent methodology following PRISMA 2020 guidelines and searched major medical databases through February 2026. The primary measures were time to DKA resolution (when acidosis and ketosis normalized) and hospital length of stay. Secondary outcomes tracked fluid volume, hypoglycemic episodes, rebound high blood glucose, DKA recurrence, electrolyte disturbances, and mortality.

The headline finding was a clear signal on resolution speed: early basal insulin reduced time to DKA resolution by 4.06 hours (95% CI -5.53 to -2.58; p < 0.0001). This effect persisted in sensitivity analysis, yielding a conservative estimate of 3.44 hours, with no heterogeneity across studies (I2 = 0%). Total fluid requirements also decreased by approximately 400 milliliters in the basal insulin group, though the clinical meaningfulness of this reduction remains modest given the volumes typically administered during DKA treatment. Meta-regression analysis found no significant effect modification by age, BMI, sample size, or sex distribution, suggesting consistency across different patient populations.

Critically, the safety profile was neutral. No significant differences emerged between groups for hospital length of stay, rebound hyperglycemia, recurrent DKA, hypoglycemic episodes, low potassium levels, or mortality. This absence of increased adverse events is essential: it means the shorter resolution time was not purchased at the cost of safety. The authors concluded that while the 4-hour reduction in DKA resolution represents a real clinical signal, larger multicentre trials are needed to confirm whether this translates to meaningfully different patient outcomes or clinical workflows.

What This Means for You

This research applies to hospitalized patients with DKA and their clinical teams, not to outpatient diabetes management. The findings suggest that adding basal insulin earlier in DKA treatment is safe and accelerates metabolic recovery, but do not establish this as a paradigm shift in emergency care.

For patients with diabetes experiencing DKA symptoms (severe thirst, rapid breathing, fruity-smelling breath, abdominal pain), the message is unchanged: seek emergency care immediately. Time to hospital treatment matters far more than which specific insulin regimen is used once you arrive.

For clinicians, the data support the safety of incorporating early basal insulin into DKA protocols where feasible, potentially reducing median hospital stay by a few hours per patient at scale. However, the neutral effect on hospital length of stay suggests this is a process improvement rather than a game-changing intervention. Standard IV insulin therapy remains the backbone of DKA management.

Study Details

Sources

Endocrinology, Diabetes & Metabolism. "Impact of Early Subcutaneous Basal Insulin With Intravenous Insulin Infusion for Diabetic Ketoacidosis and Glycaemic Outcomes: A Systematic Review and Meta-Analysis." PubMed: 42405473